 | Up a level |
Rovó, Alicia; Gras, Luuk; Piepenbroek, Brian; Kröger, Nicolaus; Reinhardt, Christian H.; Radujkovic, Aleksandar; Blaise, Didier; Kobbe, Guido; Niityvuopio, Riitta; Platzbecker, Uwe; Sockel, Katja; Hunault-Berger, Mathilde; Cornelissen, J J; Forcade, Edouard; Bourhis, Jean Henri; Chalandon, Yves; Kinsella, Francesca; Nguyen-Quoc, Stéphanie; Maertens, Johan; Elmaagacli, Ahmet; ... (2024). Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT. American journal of hematology, 99(2), pp. 203-215. Wiley-Liss 10.1002/ajh.27150
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; ... (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(7), pp. 1751-1759. Nature Publishing Group 10.1038/s41375-020-0725-0
